NCT05934331

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestinal Cancer.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 276 (estimated)
• Sponsor: LaNova Medicines Zhejiang Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

Conditions

• Malignant Neoplasms of Digestive Organs

Interventions

Type	Name	Description
DRUG	LM-302	Q2W/Q3W，Administered intravenously
DRUG	Toripalimab	Q2W/Q3W,Administered intravenously
DRUG	Capecitabine	BID,Oral Administration
DRUG	Tegafur, Gimeracil and Oteracil Potassium Capsules	BID,Oral Administration
DRUG	Nivolumab	Q4W,Administered intravenously
DRUG	Apatinib	QD,Oral Administration
DRUG	Gemcitabine	Q4W,Administered intravenously

Timeline

• Start date: 2023-07-27
• Primary completion: 2026-07-01
• Completion: 2028-07-01
• First posted: 2023-07-06
• Last updated: 2025-09-12

Locations

1 site across 1 country: China